Patents by Inventor Immanuel Luescher

Immanuel Luescher has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6060257
    Abstract: Tumor rejection antigens presented by HLA-244 molecules are described. These peptides are useful in diagnostic and therapeutic methodologies. The tumor rejection antigens are derived from MAGE tumor rejection antigen precursors.
    Type: Grant
    Filed: February 20, 1996
    Date of Patent: May 9, 2000
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Jean Herman, Pierre Coulie, Thierry Boon-Falleur, Pierre van der Bruggen, Immanuel Luescher
  • Patent number: 5827073
    Abstract: The invention relates to methods for making synthetic, photoreactive peptides and their use. A photoreactively labelled amino acid is incorporated into the peptide. The resulting peptide, when compared to the non-labelled form, is not impaired with respect to its ability to bind an MHC molecule.
    Type: Grant
    Filed: July 5, 1995
    Date of Patent: October 27, 1998
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Immanuel Luescher, Fabienee Anjuere, Andreas Layer, Pedro Romero, Jean-Charles Cerottini
  • Patent number: 5744353
    Abstract: Tumor rejection antigens presented by HLA-B44 molecules are described. These peptides are useful in diagnostic and therapeutic methodologies. The tumor rejection antigens are derived from MAGE tumor rejection antigen precursors.
    Type: Grant
    Filed: February 6, 1997
    Date of Patent: April 28, 1998
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Jean Herman, Pierre Coulie, Thierry Boon-Falleur, Pierre van der Bruggen, Immanuel Luescher